CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.
Share Price & News
How has CytomX Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTMX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CTMX's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CTMX underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: CTMX underperformed the US Market which returned 30.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is CytomX Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
3 months ago | Simply Wall StShareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
3 months ago | Simply Wall StCytomX Therapeutics (NASDAQ:CTMX) Share Prices Have Dropped 67% In The Last Three Years
CytomX Therapeutics Fundamentals Summary
|CTMX fundamental statistics|
Is CTMX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTMX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.17|
|Net Profit Margin||-96.67%|
How did CTMX perform over the long term?See historical performance and comparison
Is CytomX Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CTMX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CTMX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTMX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTMX is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.1x).
How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CTMX's revenue (0.3% per year) is forecast to grow slower than the US market (9.5% per year).
High Growth Revenue: CTMX's revenue (0.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTMX is forecast to be unprofitable in 3 years.
How has CytomX Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTMX is currently unprofitable.
Growing Profit Margin: CTMX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTMX is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare CTMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: CTMX has a negative Return on Equity (-49.03%), as it is currently unprofitable.
How is CytomX Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CTMX's short term assets ($271.0M) exceed its short term liabilities ($93.4M).
Long Term Liabilities: CTMX's short term assets ($271.0M) exceed its long term liabilities ($178.1M).
Debt to Equity History and Analysis
Debt Level: CTMX is debt free.
Reducing Debt: CTMX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTMX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CTMX has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.
What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTMX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTMX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sean McCarthy (54 yo)
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since July 2021. He has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD2.85M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Experienced Management: CTMX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: CTMX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.1%.
CytomX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: CytomX Therapeutics, Inc.
- Ticker: CTMX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$323.830m
- Shares outstanding: 65.16m
- Website: https://www.cytomx.com
Number of Employees
- CytomX Therapeutics, Inc.
- 151 Oyster Point Boulevard
- Suite 400
- South San Francisco
- United States
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatme...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:45|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.